Altogether, these findings expand the knowledge on DIS3L2 role in cancer and suggests that, given its nearly absent effects in well-differentiated and non-transformed cells, the targeting of DIS3L2 may present a novel therapeutic venue to explore in advanced CRC. This evidence concerns the gene DIS3L2 and colorectal carcinoma.